Navigation Links
AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Date:11/13/2008

for the three-month period ended September 30, 2008 compared to the same period last year, is mainly related to the advancement of the cetrorelix Phase 3 program for BPH, lower manufacturing margins and foreign exchange loss.

The cash and short-term investments were $11 million as at September 30, 2008.

CONFERENCE CALL

Management will be hosting a conference call for the investment community beginning at 10:00 a.m. Eastern Time, today, November 13, 2008, to discuss third quarter 2008 financial results. To participate in the live conference call by telephone, please dial 416-646-3095, 514-807-8791 or 800-814-4859. Individuals interested in listening to the conference call on the Internet may do so by visiting http://www.aezsinc.com. A replay will be available on the Company's Web site for 30 days.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Inves
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
2. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
4. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
5. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
6. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
8. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
9. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
10. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
11. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 22 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today ... financial results on Wednesday, October 29,2008, after the market ... call at 5:00 p.m. ET, which will be open ... call, the company will review,the financial results and discuss ...
... MONTREAL, Oct. 22 Global Vision, the leader ... that 15 of the top 20 pharmaceutical companies ... risk of textual and artwork errors from,occurring in ... has resulted in a reduction of quality issues ...
... Md., Oct. 22 Micromet, Inc.,(Nasdaq: MITI ... the treatment of cancer, inflammation and autoimmune,diseases, today ... and audio,webcast on Thursday, November 6, 2008, at ... to discuss its third quarter 2008 financial results.,Micromet ...
Cached Biology Technology:Sangamo BioSciences Announces Third Quarter Conference Call and Webcast 2Sangamo BioSciences Announces Third Quarter Conference Call and Webcast 3Global Vision Recognized for Helping Pharmaceutical Companies Achieve Complete Artwork and Copy Accuracy in their Packaging Process 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 3Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results 4
(Date:4/15/2014)... The global experts who study the deadliest infectious ... Thomas G. Ksiazek, professors at the University of Texas ... 6th annual International Symposium on Filoviruses. The filoviruses include ... to 90 percent of people infected. The current outbreak ... more than 100 deaths so far. , "This ...
(Date:4/15/2014)... University dental researchers have found a less invasive ... the mouth to study how the mouth,s natural ... isolating some specialized immune cells (white blood cells ... diseases in the mouthor reject foreign tissues, such ... more about treating and preventing such health issues ...
(Date:4/15/2014)... BETHESDA, Md. (April 15, 2014) The American ... 2014 award winners. All awards will be presented ... San Diego Marriott Hotel on Tuesday, April 29th at ... Biology (EB). , The 2014 award winners ... Jeffrey Laitman, PhD, of the Icahn School of ...
Breaking Biology News(10 mins):International research group recognizes UTMB experts 2International research group recognizes UTMB experts 3New method isolates immune cells for researchers to study how they ward off oral diseases 2American Association of Anatomists 2014 award winners 2
... Santa Barbara have discovered a caste of genetically identical ... that invades the California horn snail. The findings are ... Proceedings of the Royal Society B . "We ... defending the colony," said Armand M. Kuris, professor of ...
... Researchers at Oregon State University have reported the successful ... of nanostructure that has gained significant interest in recent ... microreactors. The findings, announced in the journal ... new nanotech applications in production of pharmaceuticals, biological sensors, ...
... Mich. A University of Michigan-led research team ... a devastating inherited kidney disorder, thanks to a new, faster ... The success offers hope that scientists can speed the ... and test drugs to treat them. The U-M ...
Cached Biology News:'Warrior worms' discovered in snails; UCSB scientists see possible biomedical applications 2'Nanosprings' offer improved performance in biomedicine, electronics 2Fast-track gene-ID method speeds rare disease search 2Fast-track gene-ID method speeds rare disease search 3
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
...
Biology Products: